Diabetes 2014;63:12241233.ArticlePubMed 81
Furthermore, the fact that these studies were conducted among different populations also limits the generalizability of the results to some extent
Bar-Peled, L
Interdisciplinary efforts integrating nanomaterial engineering, pharmacokinetic modeling, and biomarker-driven regimens are essential to address these challenges
If you're not experiencing appetite suppression by day five, or if side effects are limiting your progress, your care team adjusts your protocolwhether that means slower titration, dose stabilization, or exploring alternatives like oral semaglutide or tirzepatide
10.1016/s0928-4257(99)00124-2 [DOI] [PubMed] [Google Scholar] Sikiric P., Marovic A., Matoz W., Anic T., Buljat G., Mikus D., et al